Asset Dedication’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$186K Sell
1,150
-94
-8% -$15.7K 0.01% 332
2026
Q2
$236K Sell
1,244
-129
-9% -$24.3K 0.01% 305
2026
Q1
$271K Sell
1,373
-102
-7% -$19.7K 0.02% 278
2025
Q4
$271K Sell
1,475
-81
-5% -$14.2K 0.02% 272
2025
Q3
$239K Buy
1,556
+55
+4% +$8.32K 0.02% 310
2025
Q2
$210K Sell
1,501
-48
-3% -$6.73K 0.02% 317
2025
Q1
$228K Buy
1,549
+19
+1% +$2.75K 0.02% 280
2024
Q4
$200K Buy
1,530
+68
+5% +$9.5K 0.02% 302
2024
Q3
$228K Buy
1,462
+187
+15% +$30.2K 0.02% 310
2024
Q2
$199K Sell
1,275
-16
-1% -$2.41K 0.01% 318
2024
Q1
$166K Buy
1,291
+75
+6% +$9.9K 0.01% 315
2023
Q4
$155K Buy
+1,216
New +$158K 0.01% 321
2020
Q1
– Sell
-83
Closed -$8K – 650
2019
Q4
$8K Buy
+83
New +$7.81K ﹤0.01% 483

Other funds holding AZN

Asset Dedication's AZN Position: Q3 2026 in Review

Asset Dedication reduced its AstraZeneca (AZN) stake by 7.6% in Q3 2026, selling an estimated $15.7K and leaving 1,150 shares worth $186K. The position accounts for 0.01% of the portfolio, ranked #332.

Asset Dedication first reported a position in AZN in Q4 2019 and has held it in 13 quarters since. The position peaked at $271K in Q4 2025. 1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Asset Dedication held 1,150 shares of AstraZeneca worth $186K as of Q3 2026.
  • Asset Dedication sold 94 AstraZeneca shares in Q3 2026, an estimated $15.7K.
  • AstraZeneca made up 0.01% of Asset Dedication's portfolio in Q3 2026, its #332 holding.
  • Asset Dedication first reported a position in AstraZeneca in Q4 2019 and has held it in 13 quarters since.
  • Asset Dedication's AstraZeneca position peaked at $271K in Q4 2025.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Asset Dedication's 13F filing for Q3 2026, filed 3 Nov 2026.